Analyzing the Health Effects of Space Travel with AI

Space is a frontier for global innovation, but space doesn’t come without its limits. As exploration grows, the importance of human health in outer space grows as well. Shashi Jain, Senior Strategic Innovation Manager at Intel, and Dr. John Kalantari, Chief Technology Officer at Yrikka, Inc. spoke  with host Tyler Kern about the movement collaboration between Intel and the Frontier Development Lab an applied artificial intelligence research accelerator established to maximize new AI technologies and capacities emerging in academia and space and exploration.

The Intel and Frontier Development Lab collaboration aims to improve the data collection of astronauts. The collaboration is working to make space exploration safer and healthier through artificial intelligence. “The collaboration with Intel rose organically. We were already applying AI and machine learning in the space, specifically for decision making,” says Dr. Kalantari.

“AI, when it comes to terrestrial medicine, is suffering from the same challenges as astronaut health and space medicine,” says Dr. Kalantari, who believes part of the issue is combining the health data of astronauts safely and securely into one database. “To train an AI, you have to bring together all the data into one spot and use that to train the algorithms,” says Shashi Jain.

The risk of spending time in space is detrimental to the human body. According to NASA, when astronauts are in microgravity, the human body loses muscle mass and bone density. Physically and psychologically, the impact on human bodies could be detrimental. The mission could fail if health issues hinder a crew member on a mission.

Currently, the effects on astronauts are similar to how we gather health information on earth. Data is collected through observation and measuring vitals. “We use this collection of data before, during, and after each mission to identify any prominent biomarkers that could be indicators of disease progression,” says Jain. The main challenge of the project is maintaining the privacy of the individuals so that the collected data can train AI for the future.

For more information on the power of technology and the future of astronaut health, connect with Shashi Jain and Dr. John Kalantari on LinkedIn or explore Intel’s Health and Life Sciences page.

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Network & Edge Solutions Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More